Fondazione Poliambulanza Istituto Ospedaliero

The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study

BACKGROUND: Adjuvant chemotherapy (ACT) indication in stage II colorectal cancer (CRC) remains challenging, as clinical, pathological, and ctDNA inadequately predict benefit. Immune infiltration correlates with outcome, yet transcriptional signatures have not been systematically...

Radiographic accuracy of implant positioning in unicompartmental knee arthroplasty, does an imageless robotic system make a difference?

Abstract Background Robotic-assisted technologies and evolving implant designs have been introduced in unicompartmental knee arthroplasty (UKA) to improve the accuracy and reproducibility of component positioning. However, the relative contribution of robotic assistance compared...

Incidence and Predictors of Complications After Transcatheter Aortic Valve Implantation According to VARC‐3 Criteria: A Systematic Review and Meta‐Analysis

BACKGROUND: Despite continuous advancements in devices and techniques, transcatheter aortic valve implantation remains associated with complications impacting outcomes. In 2021, the Valve Academic Research Consortium (VARC) introduced the VARC-3 criteria to better classify proced...

Knowledge Improvement After a Neonatal Resuscitation Course in a Low-Resource Setting

Background: The application of neonatal guidelines developed for high-resource settings is often difficult in low-resource settings due to structural differences and lack of equipment and personnel. The Helping Babies Breathe (HBB) program has been developed to overcome this limi...

Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options. The addition of durvalumab or pembrolizumab to cisplatin–gemcitabine improves overall survival (OS), but validated biomarkers of benefit remain limited. Immune-mediated adverse ev...